Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light

Transfusion

Volumn 53, Issue 3, 2013, Pages 600-605

  Cid, Joan ^a   Caballo, Carolina ^a   Pino, Marc ^a   Galan, Ana M ^a   Martínez, Nuria ^a   Escolar, Ginés ^a   Diaz Ricart, Maribel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FRESH FROZEN PLASMA; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLOOD DONOR; CONTROLLED STUDY; CRYOPRECIPITATE; HUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; ULTRAVIOLET A RADIATION;

ADAM PROTEINS; BLOOD COAGULATION FACTORS; BLOOD SAFETY; CASE-CONTROL STUDIES; FACTOR VIII; FIBRINOGEN; HUMANS; MICROBIAL VIABILITY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PLASMA; PSORALENS; ULTRAVIOLET RAYS; VON WILLEBRAND FACTOR;

EID: 84874949948     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03763.x     Document Type: Article

References (28)

1. European Committee on Blood Transfusion. Guide to the preparation, use and quality assurance of blood components. 16th ed. Strasbourg: EDQM; 2011.
2. Brecher ME, Leger RM, Linden JV, Roseff SD,. Technical manual. 15th ed. Bethesda (MA): American Association of Blood Banks; 2005.
3. Schmidt PJ,. Blood component therapy from the beginning. In:, Blajchman M, Cid J, Lozano M, editors. Blood component preparation. From benchtop to bedside. 1st ed. Bethesda (MA): American Association of Blood Banks; 2011. p. 1-22.
4. The Standards program committee of the AABB. Standards for blood banks and transfusion services. 23rd ed. Bethesda (MA): American Association of Blood Banks; 2005.
5. Lozano M,. Pathogen-inactivation technologies for blood components. In:, Blajchman M, Cid J, Lozano M, editors. Blood component preparation. From benchtop to bedside. 1st ed. Bethesda (MD): American Association of Blood Banks; 2011. p. 247-70.
6. Solheim BG, Hellstern P,. Pathogen inactivation of plasma and cryoprecipitate. In:, AuBuchon JP, Prowse CV, editors. Pathogen inactivation of. The penultimate paradigm shift. 1st ed. Bethesda (MA): American Association of Blood Banks; 2010. p. 69-98.
7. Corash L,. Virus-safe products: pathogen reduction and inactivation. In:, Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD, editors. Blood banking and transfusion medicine. 1st ed. Philadelphia (PA): Elsevier; 2007. p. 383-96.
8. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L,. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46: 1168-77.
9. Osselaer JC, Debry C, Goffaux M, Pineau J, Calomme G, Dubuc E, Chatelain B, Vandendaele MC, Hsu J, Rheinschmidt M, Lin L,. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48: 108-17.
10. Cid J, Ramiro L, Martinez N, Palomo M, Magallon O, Claparols M, Ortiz P, Puig L, Pla RP,. Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfus Apher Sci 2008; 39: 115-21.
11. de AP, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L,. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45: 1362-72.
12. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van DS, Corash L,. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-60.
13. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG,. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693-704.
14. Cid J, Claparols M, Pinacho A, Hernandez JM, Ortiz P, Puig LS, Pla RP,. Comparison of blood component preparation methods from whole blood bags based on buffy coat extraction. Transfus Apher Sci 2007; 36: 243-7.
15. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T,. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
16. Cumming AM, Wensley RT,. Analysis of von Willebrand factor multimers using a commercially available enhanced chemiluminescence kit. J Clin Pathol 1993; 46: 470-3.
17. Keeling DM, Luddington R, Allain JP, Lawrie AS, Williamson LM,. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 1997; 96: 194-7.
18. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M,. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 2006; 91: 56-62.
19. Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, El-Ekiaby M,. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. Haemophilia 2008; 14: 956-62.
20. Aznar JA, Montoro JM, Cid AR, Bonanad S, Hurtado C, Soler MA, De MA,. Clotting factors in cryoprecipitate and cryo-supernatant prepared from MB-treated fresh plasma. Transfusion 2000; 40: 493.
21. Aznar JA, Bonanad S, Montoro JM, Hurtado C, Cid AR, Soler MA, De MA,. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000; 79: 156-60.
22. Hornsey VS, Krailadsiri P, MacDonald S, Seghatchian J, Williamson LM, Prowse CV,. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol 2000; 109: 665-70.
23. Hornsey V, Young D, Prowse C,. Cryoprecipitate prepared from methylene blue-treated fresh plasma. Transfusion 2001; 41: 151-2.
24. Hornsey VS, Young DA, Docherty A, Hughes W, Prowse CV,. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Transfus Med 2004; 14: 369-74.
25. Rock G,. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-78.
26. Sorensen B, Bevan D,. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149: 834-43.
27. Franchini M, Lippi G,. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus 2012; 10: 23-7.
28. Theodoulou A, Berryman J, Nathwani A, Scully M,. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia. Transfus Apher Sci 2012; 46: 159-62.